Search Team

Search by Last Name
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
 

Background

Ron Vogel is a litigation Associate in the New York office of Fish & Richardson.  His life sciences practice involves litigation, licensing, and counseling services in the biotechnology, pharmaceuticals, and medical devices fields.  His regulatory practice focuses on FDA work, including pharmaceutical approvals, drug exclusivities and patent protection under the Hatch-Waxman Act as well as biosimilar approvals and patent litigation procedures under the Biologics Price Competition and Innovation Act.

Ron has a master’s and a bachelor’s degree in chemical engineering from Cooper Union.  Prior to joining the firm, Ron worked as chemist in the consumer products industry.  His prior technical experience includes research at the National Institutes of Health Laboratory of Immunology.

Ron also holds a second bachelor’s degree in finance and has experience in commercial litigation, including suits filed under the False Claims Act.  He worked as a Financial Analyst at an international bank early in his career, and plans to complete his Chartered Financial Analyst (CFA) certification in the near future.  Ron was previously a Summer Associate in the New York office in 2012.

Education

J.D., Fordham University School of Law 2013
magna cum laude


M.E., Cooper Union for the Advancement of Science and Art 2015
Chemical Engineering


B.E., Cooper Union for the Advancement of Science and Art 2001
Chemical Engineering
magna cum laude


B.S., Rensselaer Polytechnic Institute
Finance

Admissions

  • U.S. Patent and Trademark Office 2011
  • New York 2014
  • U.S. District Court for the Eastern District of New York 2014
  • U.S. District Court for the Southern District of New York 2014
  • U.S. Court of Appeals for the Federal Circuit 2015

Other Distinctions

Publications and Patents

First Biosimilar Monoclonal Antibody in Oncology Granted EU Approval: Implications for the U.S. Market” co-authored with Tasha Francis and Jenny Shmuel, Fish Litigation Blog, (March 14, 2017).

Safe Harbor in the United States and Europe” co-authored with Brian Coggio, (Dec. 2, 2016).

Can Reference Product Sponsor Forfeit Right To Sue Under BPCIA?” co-authored with Brian Coggio, Law360 (July 25, 2016).

What the Court Got Wrong About Hatch-Waxman in Alcon” co-authored with Brian Coggio, Law360 (February 1, 2016).

Fed. Cir. Limits Safe Harbor for Post-Approval Conduct” co-authored with Brian Coggio, Law360 (November 17, 2015).

Safe Harbor Protects Supplier of Active Ingredient for ANDA,” with Brian Coggio, Law360 (September 29, 2015).

Should A Good Faith Belief in Patent Invalidity Negate Induced Infringement? (The Trouble with Commil is DSU),” with Brian Coggio, IPO Law Journal (February 12, 2015).

The Trouble with Commil is DSU,” with Brian Coggio, Law360 and IPO Law Journal (January 29, 2015).

The BPCIA “Patent Dance”–Waiting for the Music to Begin,” with Terry G. Mahn, Pharmaceutical Compliance Monitor (January 22, 2015).

Is Stockpiling Protected By Hatch-Waxman Safe Harbor?,” Law360 (November 21, 2014).

The Patent Pilot Program: Reassignment Rates and the Effect of Local Patent Rules“, NYIPLA Bulletin (October/November 2013).

The Great Brain Robbery: Tianrui and the Treatment of Extraterratorial Unfair Trade Acts,” The Federal Circuit Bar Journal, 22 Fed. Cir. B.J. 641 (July 2013).

Clearly and Convincingly: The Supreme Court weighs in on Microsoft v. i4i,” Fordham Intellectual Property, Media & Entertainment Law Journal Blog (July 2011).

From Bon Tool to Bowties: the Patent Marking Landscape after Stauffer,” Fordham Intellectual Property, Media & Entertainment Law Journal Blog (October 11, 2010).

Ben-Sasson, S. Z.; Zukovsky, I.; Biton, A., Vogel, R.; Foucras, G.; Hayashi, N., Paul, W.E. “Generation and Characterization of Memory CD4 T Cells” Adv Exp Med Biol., 2002. 512: 129-34.

What's trending with Ron

Filter by
Fish Litigation Blog
March 14, 2017
First Biosimilar Monoclonal Antibody in Oncology Granted EU Approval: Implications for the U.S. Market
First Biosimilar Monoclonal Antibody in Oncology Granted EU Approval:  Implications for the U.S. Market
Authors: Jenny Shmuel, Ph.D., Ron Vogel, Tasha M. Francis, Ph.D.
IP Litigation
Life Sciences
News
February 17, 2017
Fish Files Amicus Brief in Support of Challenge to Immigration Executive Order
Event
January 19th, 2017 | 1:00 pm EST
Understanding the US Safe Harbor, and Regulatory and Research Safe Harbors in the EU/Canada
Understanding the US Safe Harbor, and Regulatory and Research Safe Harbors in the EU/Canada
Webinar
Fish Litigation Blog
July 25, 2016
Can Reference Product Sponsor Forfeit Right To Sue Under BPCIA?
Can Reference Product Sponsor Forfeit Right To Sue Under BPCIA?
Authors: Brian D. Coggio, Ron Vogel
IP Litigation
Life Sciences
News
April 6, 2016
Real Party-in-Interest in Post-Grant Proceedings
Articles
News
June 12, 2015
Brian Coggio and Ron Vogel Author "Hatch-Waxman Actions: Who Do You (Can You) Sue?"
Articles
Fish Litigation Blog
December 7, 2016
Survey of the Safe Harbor in the United States and Europe
Survey of the Safe Harbor in the United States and Europe
Authors: Brian D. Coggio, Ron Vogel
IP Litigation
Life Sciences
News
November 18, 2015
"Fed. Cir. Limits Safe Harbor for Post-Approval Conduct"
Articles
Legal Alerts
News
September 30, 2015
"Safe Harbor Protects Supplier of Active Ingredient for ANDA"
Legal Alerts
Event
March 11th, 2015 | 1:00 pm EDT
BRI, after Cuozzo, and RPI Factors in Post-Grant Proceedings
Speaking Engagement
Webinar
Event
July 9th, 2014
More from the PTAB: Prosecution Bars, CBM, and Motions to Exclude
Speaking Engagement
Webinar
Event
July 24th, 2014
NYIPLA Second Circuit Moot Court Argument
load more topics